About Human Genome Sciences
Human Genome Sciences is a company based in Rockville (United States) founded in 1992 was acquired by Samsung BioLogics in December 2025. Human Genome Sciences operates in a competitive market with competitors including BeiGene, Moderna, Incyte, Regeneron Pharmaceuticals and MorphoSys, among others.
- Headquarter Rockville, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
GSK
& 1 more
-
Employee Count
Not available
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Human Genome Sciences
Detailed funding history for Human Genome Sciences
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Human Genome Sciences
Human Genome Sciences has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include GSK and Samsung BioLogics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
Locked | Locked | Locked | |
|
Contract development and manufacturing for biologics are provided.
|
Locked | Locked | Locked |
Investor details for Human Genome Sciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Human Genome Sciences
Investment portfolio details for Human Genome Sciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Human Genome Sciences
Detailed financials for Human Genome Sciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Human Genome Sciences Comparisons
Peer comparison for Human Genome Sciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Human Genome Sciences
Human Genome Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Moderna, Incyte, Regeneron Pharmaceuticals and MorphoSys, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Human Genome Sciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Human Genome Sciences
Complete news archive for Human Genome Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Human Genome Sciences
Human Genome Sciences was founded in 1992.
Human Genome Sciences is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Human Genome Sciences was established in 1992 in Rockville, United States, within the biotechnology sector. Protein and antibody drugs were developed using human DNA sequences, targeting lupus, hepatitis C, inhalation anthrax, and cancer. A pipeline of seven products addressed autoimmune diseases, anthrax exposure, and oncology. Collaboration with Cambridge Antibody Technology yielded therapeutics such as belimumab and raxibacumab. Acquisition by GlaxoSmithKline occurred in 2012 for 3 billion.
Human Genome Sciences's top competitors include Moderna, BeiGene and Regeneron Pharmaceuticals.
Human Genome Sciences has 2 investors. Key investors include GSK, and Samsung BioLogics.